Robert Kreitman
Hematology & Oncology · Olney, MDNPI 1043499312
Payments from drug & device makers
What this record shows
Every reported general payment came from a single manufacturer, AstraZeneca. That places this record below the midpoint for hematology & oncology clinicians in MD, where the typical reported total is $2,111.
Across 3 payments — averaging $90.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$270
Across 61 payments — averaging $888,554 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$33.4M
- Pfizer$18M
- AstraZeneca$1.4M
- Teva Pharmaceuticals USA, Inc.$1.2M
- Innate Pharma, Inc$212K
What the payments were for
- Travel & lodging$15557%
- Food & beverage$11543%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 3 | $270 |
How this compares
$270 in reported general payments places this provider in the 20th percentile of 242 hematology & oncology providers in Maryland.
Other hematology & oncology in Olney
- Ralph BocciaBethesda$3.1M
- Sandra SwainBethesda$1M
- Kashif AliSilver Spring$987K
- Ani BalmanoukianBaltimore$842K
- Benjamin LevyBaltimore$578K
- Patrick FordeBaltimore$269K
- Noah HahnBaltimore$133K
- Walid El AyassSalisbury$111K
- Arun BhandariAnnapolis$103K
- Huzefa BahrainBaltimore$102K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.